ASCO 2021 | Progression patterns in post-ipilimumab and anti-PD-1 in metastatic melanoma

Ines Pires Da Silva, MD, PhD, Melanoma Institute Australia, Sydney, New South Wales, Australia & The University of Sydney Central Clinical School, Sydney, New South Wales, Australia, provides an overview of various progression patterns in patients with metastatic melanoma after receiving first-line ipilimumab combined with anti-PD-1 treatment. In a group of 301 patients, patterns of progression were categorized as innate progression, acquired resistance, or pseudoprogression. Management and outcomes of different types of progression were additionally discussed, with BRAF/MEK inhibitors improving overall survival (OS) and chemotherapy having no effect on OS. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.